GB202108523D0 - Compositions and their use for the treatment of alpha1-antitrypsin deficiency - Google Patents

Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Info

Publication number
GB202108523D0
GB202108523D0 GBGB2108523.8A GB202108523A GB202108523D0 GB 202108523 D0 GB202108523 D0 GB 202108523D0 GB 202108523 A GB202108523 A GB 202108523A GB 202108523 D0 GB202108523 D0 GB 202108523D0
Authority
GB
United Kingdom
Prior art keywords
alpha1
compositions
treatment
antitrypsin deficiency
antitrypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108523.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Z Factor Ltd
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Priority to GBGB2108523.8A priority Critical patent/GB202108523D0/en
Publication of GB202108523D0 publication Critical patent/GB202108523D0/en
Priority to IL309355A priority patent/IL309355A/en
Priority to CN202280053656.2A priority patent/CN117794538A/zh
Priority to PCT/GB2022/051502 priority patent/WO2022263816A1/en
Priority to BR112023026510A priority patent/BR112023026510A2/pt
Priority to MX2023015398A priority patent/MX2023015398A/es
Priority to EP22735956.9A priority patent/EP4355328A1/en
Priority to JP2023577946A priority patent/JP7854001B2/ja
Priority to CA3223130A priority patent/CA3223130A1/en
Priority to KR1020247001332A priority patent/KR20240027693A/ko
Priority to AU2022295130A priority patent/AU2022295130A1/en
Priority to US18/540,695 priority patent/US12673050B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB2108523.8A 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency Ceased GB202108523D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
AU2022295130A AU2022295130A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY
BR112023026510A BR112023026510A2 (pt) 2021-06-15 2022-06-15 Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina
CN202280053656.2A CN117794538A (zh) 2021-06-15 2022-06-15 用于治疗α1-抗胰蛋白酶缺乏症的组合物及其用途
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY
IL309355A IL309355A (en) 2021-06-15 2022-06-15 Compositions and their use for the treatment of α1-antitrypsin deficiency
MX2023015398A MX2023015398A (es) 2021-06-15 2022-06-15 Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina.
EP22735956.9A EP4355328A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF alpha1-ANTITRYPSIN DEFICIENCY
JP2023577946A JP7854001B2 (ja) 2021-06-15 2022-06-15 α１－アンチトリプシン欠乏症の処置のための組成物およびそれらの使用
CA3223130A CA3223130A1 (en) 2021-06-15 2022-06-15 Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency
KR1020247001332A KR20240027693A (ko) 2021-06-15 2022-06-15 α1-항트립신 결핍의 치료를 위한 조성물 및 그의 용도
US18/540,695 US12673050B2 (en) 2021-06-15 2023-12-14 Compositions and their use for the treatment of A1-antitrypsin deficiency

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Publications (1)

Publication Number Publication Date
GB202108523D0 true GB202108523D0 (en) 2021-07-28

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108523.8A Ceased GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Country Status (12)

Country Link
US (1) US12673050B2 (enExample)
EP (1) EP4355328A1 (enExample)
JP (1) JP7854001B2 (enExample)
KR (1) KR20240027693A (enExample)
CN (1) CN117794538A (enExample)
AU (1) AU2022295130A1 (enExample)
BR (1) BR112023026510A2 (enExample)
CA (1) CA3223130A1 (enExample)
GB (1) GB202108523D0 (enExample)
IL (1) IL309355A (enExample)
MX (1) MX2023015398A (enExample)
WO (1) WO2022263816A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP3391038B2 (ja) 1991-12-26 2003-03-31 富士レビオ株式会社 カルボン酸アミド誘導体
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
WO2012097371A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
CN110325527B (zh) 2016-12-09 2022-08-09 勃林格殷格翰国际有限公司 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺
CA3103920C (en) 2018-06-22 2025-09-16 Ucl Business Ltd COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Also Published As

Publication number Publication date
JP7854001B2 (ja) 2026-04-30
US12673050B2 (en) 2026-07-07
JP2024523406A (ja) 2024-06-28
US20240197707A1 (en) 2024-06-20
AU2022295130A1 (en) 2024-01-18
MX2023015398A (es) 2024-04-29
BR112023026510A2 (pt) 2024-03-05
CN117794538A (zh) 2024-03-29
KR20240027693A (ko) 2024-03-04
CA3223130A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
ZA202103977B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL297849B1 (en) Composition for use in the treatment of APOL1-related disease
IL308221A (en) Preparations and methods for treating depression
ZA202207493B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
GB2613460B (en) Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
IL312928A (en) Complement Factor B Modulating Preparations and Methods for Using Them
IL312583A (en) A preparation for the treatment and prevention of COVID-19
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
IL319307A (en) Compositions and methods for preventing and treating orthopoxvirus infections
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB202406893D0 (en) Therapeutic and preventive compositions
IL309355A (en) Compositions and their use for the treatment of α1-antitrypsin deficiency
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
HK40111012A (en) Compositions and their use for the treatment of alpha1-antitrypsin deficiency
IL318680A (en) Pharmaceutical preparations and their uses for the treatment of glioma
GB202108543D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108544D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108542D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
PL4346847T3 (pl) Kompleks wielojonowy do stosowania w profilaktyce lub leczeniu zapalenia neurogennego
PL4168523T3 (pl) Kompozycje i ich zastosowanie
GB202212451D0 (en) Methods and compositions for the treatment of hemangioma
HK40076794A (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB2610895B (en) Composition for use in the treatment and/or prevention of mycotoxic disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)